277 related articles for article (PubMed ID: 21320556)
41. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
[TBL] [Abstract][Full Text] [Related]
42. Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.
Van den Eynde E; Quer J; Cubero M; Curran A; Homs M; Garcia-Cehic D; Falco V; Ribera E; Esteban JI; Pahissa A; Crespo M
Antivir Ther; 2011; 16(6):887-93. PubMed ID: 21900721
[TBL] [Abstract][Full Text] [Related]
43. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
Ölschläger S; Neyts J; Günther S
Antiviral Res; 2011 Aug; 91(2):89-93. PubMed ID: 21616094
[TBL] [Abstract][Full Text] [Related]
44. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors.
Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE
Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631
[TBL] [Abstract][Full Text] [Related]
45. Multiple effects of Honokiol on the life cycle of hepatitis C virus.
Lan KH; Wang YW; Lee WP; Lan KL; Tseng SH; Hung LR; Yen SH; Lin HC; Lee SD
Liver Int; 2012 Jul; 32(6):989-97. PubMed ID: 22098176
[TBL] [Abstract][Full Text] [Related]
46. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus.
Nakamura M; Saito H; Ikeda M; Hokari R; Kato N; Hibi T; Miura S
World J Gastroenterol; 2010 Jan; 16(2):184-92. PubMed ID: 20066737
[TBL] [Abstract][Full Text] [Related]
47. Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.
Galli A; Mens H; Gottwein JM; Gerstoft J; Bukh J
Sci Rep; 2018 Mar; 8(1):4619. PubMed ID: 29545599
[TBL] [Abstract][Full Text] [Related]
48. A serine palmitoyltransferase inhibitor blocks hepatitis C virus replication in human hepatocytes.
Katsume A; Tokunaga Y; Hirata Y; Munakata T; Saito M; Hayashi H; Okamoto K; Ohmori Y; Kusanagi I; Fujiwara S; Tsukuda T; Aoki Y; Klumpp K; Tsukiyama-Kohara K; El-Gohary A; Sudoh M; Kohara M
Gastroenterology; 2013 Oct; 145(4):865-73. PubMed ID: 23791700
[TBL] [Abstract][Full Text] [Related]
49. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
Tokumoto Y; Hiasa Y; Uesugi K; Watanabe T; Mashiba T; Abe M; Kumagi T; Ikeda Y; Matsuura B; Onji M
J Infect Dis; 2012 Apr; 205(7):1121-30. PubMed ID: 22357660
[TBL] [Abstract][Full Text] [Related]
50. Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?
Galmozzi E; Aghemo A; Colombo M
Med Hypotheses; 2012 Oct; 79(4):471-3. PubMed ID: 22824093
[TBL] [Abstract][Full Text] [Related]
51. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
Chou WW; Huang CF; Yeh ML; Tsai YS; Hsieh MY; Huang CI; Huang JF; Tsai PC; Hsi E; Juo SH; Tsai WL; Chuang WL; Yu ML; Dai CY
J Mol Med (Berl); 2016 Mar; 94(3):311-20. PubMed ID: 26489607
[TBL] [Abstract][Full Text] [Related]
52. Antiviral activity against the hepatitis C virus (HCV) of 1-indanone thiosemicarbazones and their inclusion complexes with hydroxypropyl-β-cyclodextrin.
Glisoni RJ; Cuestas ML; Mathet VL; Oubiña JR; Moglioni AG; Sosnik A
Eur J Pharm Sci; 2012 Oct; 47(3):596-603. PubMed ID: 22885176
[TBL] [Abstract][Full Text] [Related]
53. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of the replication of a hepatitis C virus-like RNA template by interferon and 3'-deoxycytidine.
King RW; Zecher M; Jefferies MW
Antivir Chem Chemother; 2002 Nov; 13(6):363-70. PubMed ID: 12718408
[TBL] [Abstract][Full Text] [Related]
55. Ribavirin induces widespread accumulation of IMP dehydrogenase into rods/rings structures in multiple major mouse organs.
Keppeke GD; Calise SJ; Chan EKL; Andrade LEC
Antiviral Res; 2019 Feb; 162():130-135. PubMed ID: 30605724
[TBL] [Abstract][Full Text] [Related]
56. Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes.
Testoni B; Durantel D; Lebossé F; Fresquet J; Helle F; Negro F; Donato MF; Levrero M; Zoulim F
Gut; 2016 Apr; 65(4):672-82. PubMed ID: 26082258
[TBL] [Abstract][Full Text] [Related]
57. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.
Coelmont L; Paeshuyse J; Windisch MP; De Clercq E; Bartenschlager R; Neyts J
Antimicrob Agents Chemother; 2006 Oct; 50(10):3444-6. PubMed ID: 17005827
[TBL] [Abstract][Full Text] [Related]
58. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
[TBL] [Abstract][Full Text] [Related]
59. Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Ikeda M; Kawai Y; Mori K; Yano M; Abe K; Nishimura G; Dansako H; Ariumi Y; Wakita T; Yamamoto K; Kato N
Liver Int; 2011 Jul; 31(6):871-80. PubMed ID: 21645219
[TBL] [Abstract][Full Text] [Related]
60. Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives.
Salim MT; Aoyama H; Sugita K; Watashi K; Wakita T; Hamasaki T; Okamoto M; Urata Y; Hashimoto Y; Baba M
Biochem Biophys Res Commun; 2011 Dec; 415(4):714-9. PubMed ID: 22085716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
